Last reviewed · How we verify
MYL-1401A (Adalimumab)
MYL-1401A is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
MYL-1401A is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | MYL-1401A (Adalimumab) |
|---|---|
| Sponsor | Mylan Inc. |
| Drug class | TNF-α inhibitor (monoclonal antibody biosimilar) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Adalimumab is a fully human monoclonal antibody that targets TNF-α, a key pro-inflammatory cytokine. By binding to TNF-α, it prevents interaction with TNF receptors on immune cells and tissues, thereby suppressing inflammatory responses. MYL-1401A is Mylan's biosimilar version designed to have equivalent efficacy and safety to the reference adalimumab product.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriasis
- Psoriatic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Serious infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MYL-1401A (Adalimumab) CI brief — competitive landscape report
- MYL-1401A (Adalimumab) updates RSS · CI watch RSS
- Mylan Inc. portfolio CI